This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ben-Zeev, B. Articles by Blatt, I. Search for Related Content PubMed PubMed Citation Articles by Ben-Zeev, B. Articles by Blatt, I. Social Bookmarking                         What's this?

Oligohydrosis and Hyperthermia: Pilot Study of a Novel Topiramate Adverse Effect

Pediatric Neurology Unit, Sheba Medical Center, Ramat-Gan, Israel, benzeev4{at}netvision.net.il.

Nathan Watemberg, MD

Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel

Arie Augarten, MD

Pediatric Pulmonology Unit, Sheba Medical Center, Ramat-Gan, Israel, Pediatric Neurology Department, Long Island Jewish Hospital, New York, NY

Nathan Brand, MD

Pediatric Neurology Unit, Sheba Medical Center, Ramat-Gan, Israel

Yaakov Yahav, MD

Pediatric Pulmonology Unit, Sheba Medical Center, Ramat-Gan, Israel

Ori Efrati, MD

Pediatric Pulmonology Unit, Sheba Medical Center, Ramat-Gan, Israel

Leon Topper, MD

Ilan Blatt, MD

Neurology Department, Sheba Medical Center, Ramat-Gan, Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

A 6-year-old boy with partial complex seizures developed recurrent episodes of hyperthermia 2 months after topiramate was introduced into his antiepilepsy drug regimen. Further investigation revealed that the febrile episodes were related to environmental temperature and physical activity. A pilocarpine iontophoresis sweat test showed that the amount of sweat produced by the child was 5% that of age-matched controls. Topiramate discontinuation resulted in the disappearance of febrile episodes and normalization of sweat quantity in repeat sweat testing. Based on this observation and the previous data on zonisamide and isolated case reports on topiramate-related hyperthermia and the effect on sweat production, topiramate was suspected of causing oligohydrosis. A pilot study was carried out involving 13 additional children and young adults (age range 1—37 years) receiving topiramate. All patients were directly questioned regarding symptoms of decreased sweating and heat intolerance, went through a pilocarpine iontophoresis sweat test, and were compared with 14 age-matched controls who went through the sweat test for unrelated reasons. Nine of the patients were found to have reduced sweat quantity on the pilocarpine iontophoresis sweat test (including index case) (mean 0.089 g/30 minutes, SD 0.082; age-matched control: mean 0.21 g/30 minutes, SD 0.06). Eight of them were children (below 16 years). However, only three patients revealed symptoms related to heat intolerance. Topiramate is most likely responsible for decreased sweat production as detected by a pilocarpine iontophoresis sweat test. The effect seems to be more significant in children than in adults. There is a discrepancy between test results and clinical symptoms. Interestingly, oligohydrosis was found to be a relatively common side effect of zonisamide. Both zonisamide and topiramate share a carbonic anhydrase inhibitor activity. The significance of oligohydrosis in hot climates should not be underestimated. Its extent, the role of sweat test prediction, and clinical significance during topiramate treatment should be further estimated. (J Child Neurol 2003;18:254—257).

Journal of Child Neurology, Vol. 18, No. 4, 254-257 (2003)
DOI: 10.1177/08830738030180041001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Korinthenberg and A. Schreiner Topiramate in Children With West Syndrome: A Retrospective Multicenter Evaluation of 100 Patients J Child Neurol, March 1, 2007; 22(3): 302 - 306. [Abstract] [PDF]

				S. Grosso, E. Franzoni, P. Iannetti, G. Incorpora, C. Cardinali, I. Toldo, A. Verrotti, F. C. Moscano, V. Lo Faro, L. Mazzone, et al. Efficacy and Safety of Topiramate in Refractory Epilepsy of Childhood: Long-Term Follow-Up Study J Child Neurol, November 1, 2005; 20(11): 893 - 897. [Abstract] [PDF]

				E. K. Ziad, A. C. Rahi, S. A. Hamdan, and M. A. Mikati Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia Neurology, October 11, 2005; 65(7): 1139 - 1140. [Full Text] [PDF]

				J. A. Racoosin and J. F. Knudsen Safety of Newer Antiepileptic Drugs JAMA, May 5, 2004; 291(17): 2074 - 2074. [Full Text] [PDF]